Full results & analysis
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Angiotensin-(1-7) for Severe COVID-19
NCT04633772Phase 2
Key facts
- Status
- Completed
- Start
- Aug 2020
- Primary completion
- Nov 2021
- Countries
- 1
- Sponsor
- Erasmus Hospital
- Modality
- Peptides
- Drugs
- angiotensin-(1-7)
- Conditions
- coronavirus disease 2019 (COVID-19)
01
Overview
Phase 2, randomised, double-blind trial in coronavirus disease 2019 (COVID-19) comparing Angiotensin-(1-7) with Placebo (2 arms). Primary endpoint: Supplemental Oxygen-Free Days at 28 days. Started Aug 2020; status: completed.
02
Design
2 arms- Study design
- RandomizedDouble-blind
Angiotensin-(1-7)
Intravenous supplementation of Angiotensin-(1-7)
Placebo
NaCl 0.9%
03
Who it enrols
Adult patients admitted to ICU with severe COVID-19 pneumonia. Excludes pregnant women, cancer, hemodynamic instability, immunocompromised, heart failure, decompensated cirrhosis, HIV, dialysis, and long-term oxygen therapy.
04
Endpoints
Primary
Supplemental Oxygen-Free Days
Secondary
Hospital Length of Stay
Ventilator Free Days
ICU Free Days
RAS Effectors Levels
CT Scan Findings
C Reactive Protein
Vasopressor Usage
Chest X-ray Findings
Beyond the preview
Go deeper on NCT04633772.
Full results, competitive context and analysis are in the Gosset platform.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04633772.